PE20150323A1 - Virus de la enfermedad de marek modificado y vacunas elaboradas con el - Google Patents

Virus de la enfermedad de marek modificado y vacunas elaboradas con el

Info

Publication number
PE20150323A1
PE20150323A1 PE2014001444A PE2014001444A PE20150323A1 PE 20150323 A1 PE20150323 A1 PE 20150323A1 PE 2014001444 A PE2014001444 A PE 2014001444A PE 2014001444 A PE2014001444 A PE 2014001444A PE 20150323 A1 PE20150323 A1 PE 20150323A1
Authority
PE
Peru
Prior art keywords
disease virus
vaccine
vaccines made
marek
marek disease
Prior art date
Application number
PE2014001444A
Other languages
English (en)
Inventor
Joyce Pritchard
Teshome Mebatsion
Michel Bublot
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of PE20150323A1 publication Critical patent/PE20150323A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UNA VACUNA PARA COMBATIR LA ENFERMEDAD DE MAREK, ELABORADA A PARTIR DE UN VIRUS DE LA ENFERMEDAD DE MAREK (MDV) RECOMBINANTE DE LA CEPA CVI988, QUE HA SIDO TRANSFORMADA CON UNA CONSTRUCCION DE ADN EXOGENO QUE COMPRENDE LA SECUENCIA DE LA REPETICION TERMINAL LARGA DE UN VIRUS DE LA RETICULOENDOTELIOSIS. ASIMISMO, SE REFIERE A FORMULACIONES DE ESTA VACUNA JUNTO CON VEHICULOS O DILUYENTES FARMACEUTICAMENTE ACEPTABLES. LA VACUNA DE LA INVENCION ES UTIL PARA LA INMUNIZACION DE POLLOS FRENTE A MDV VIRULENTOS
PE2014001444A 2012-03-22 2013-03-15 Virus de la enfermedad de marek modificado y vacunas elaboradas con el PE20150323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261614142P 2012-03-22 2012-03-22

Publications (1)

Publication Number Publication Date
PE20150323A1 true PE20150323A1 (es) 2015-03-05

Family

ID=48045766

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001444A PE20150323A1 (es) 2012-03-22 2013-03-15 Virus de la enfermedad de marek modificado y vacunas elaboradas con el

Country Status (28)

Country Link
US (3) US20130251737A1 (es)
EP (2) EP2827898B1 (es)
JP (1) JP2015512396A (es)
KR (5) KR102586316B1 (es)
CN (1) CN104602706A (es)
AP (1) AP2014007955A0 (es)
AR (1) AR090472A1 (es)
BR (1) BR112014023398A8 (es)
CA (1) CA2868099C (es)
CR (1) CR20140432A (es)
DO (1) DOP2014000215A (es)
EA (1) EA030866B1 (es)
EC (1) ECSP14023407A (es)
ES (1) ES2663610T3 (es)
GE (1) GEP201706650B (es)
GT (1) GT201400199A (es)
HK (1) HK1255682A1 (es)
IL (1) IL234721B (es)
MA (1) MA37432A1 (es)
MX (1) MX355332B (es)
MY (1) MY169061A (es)
NL (1) NL301087I2 (es)
PE (1) PE20150323A1 (es)
PH (1) PH12014502085B1 (es)
TN (1) TN2014000393A1 (es)
UA (1) UA117345C2 (es)
WO (1) WO2013142377A2 (es)
ZA (1) ZA201406884B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2014007955A0 (en) * 2012-03-22 2014-09-30 Merial Ltd Modified marek's disease virus, and vaccines made therefrom
CN106397602B (zh) * 2016-08-02 2019-06-18 青岛明勤生物科技有限公司 一种分子佐剂加强型鸡马立克氏病蛋白工程疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642574A (en) 1970-04-29 1972-02-15 Us Agriculture Method for producing vaccine for immunization of poultry against marek{3 s disease
US4160024A (en) 1978-05-01 1979-07-03 Cornell Research Foundation, Inc. Marek's disease vaccine
NL8401120A (nl) 1984-04-09 1985-11-01 Centraal Diergeneeskundig Inst Viruspreparaat, waarmee gevaccineerd kan worden tegen de ziekte van marek.
US4895717A (en) 1987-07-10 1990-01-23 The United States Of America As Represented By The Secretary Of Agriculture Revertant serotype 1 Marek's disease vaccine
US4895718A (en) 1987-07-10 1990-01-23 The United States Of America, As Represented By The Secretary Of Agriculture Serotype 2 Marek's disease vaccine
BR9810369A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
US20050019348A1 (en) * 2003-07-21 2005-01-27 Reddy Sanjay M. Marek's disease virus vaccine
AP2014007955A0 (en) * 2012-03-22 2014-09-30 Merial Ltd Modified marek's disease virus, and vaccines made therefrom
US9113301B1 (en) 2014-06-13 2015-08-18 Snapchat, Inc. Geo-location based event gallery

Also Published As

Publication number Publication date
GT201400199A (es) 2018-10-15
KR20220008945A (ko) 2022-01-21
PH12014502085A1 (en) 2014-11-24
EA030866B1 (ru) 2018-10-31
EA201401044A1 (ru) 2015-01-30
PH12014502085B1 (en) 2014-11-24
BR112014023398A8 (pt) 2022-08-16
CN104602706A (zh) 2015-05-06
ECSP14023407A (es) 2015-06-30
EP3326646A1 (en) 2018-05-30
MA37432A1 (fr) 2016-03-31
US20230310589A1 (en) 2023-10-05
KR20190100431A (ko) 2019-08-28
DOP2014000215A (es) 2015-04-15
KR20230145532A (ko) 2023-10-17
US20130251737A1 (en) 2013-09-26
GEP201706650B (en) 2017-03-27
CR20140432A (es) 2015-01-09
BR112014023398A2 (pt) 2017-07-11
KR102586316B1 (ko) 2023-10-06
NL301087I2 (nl) 2022-03-11
UA117345C2 (uk) 2018-07-25
US11510978B2 (en) 2022-11-29
EP2827898A2 (en) 2015-01-28
KR20230028595A (ko) 2023-02-28
MX355332B (es) 2018-04-16
US20190216920A1 (en) 2019-07-18
ZA201406884B (en) 2015-11-25
WO2013142377A3 (en) 2014-01-23
IL234721B (en) 2018-05-31
KR20140146136A (ko) 2014-12-24
CA2868099A1 (en) 2013-09-26
HK1255682A1 (zh) 2019-08-23
CA2868099C (en) 2020-12-15
KR102503316B1 (ko) 2023-02-23
ES2663610T3 (es) 2018-04-16
WO2013142377A2 (en) 2013-09-26
TN2014000393A1 (en) 2015-12-21
MY169061A (en) 2019-02-12
AR090472A1 (es) 2014-11-12
AP2014007955A0 (en) 2014-09-30
EP2827898B1 (en) 2017-12-20
MX2014011388A (es) 2014-10-14
JP2015512396A (ja) 2015-04-27

Similar Documents

Publication Publication Date Title
EA201890999A1 (ru) Вакцина против вируса простого герпеса
PH12018501602A1 (en) Subunit immersion vaccines for fish
BR112014009565A2 (pt) vírus da doença de marek não patogênico recombinante, ácido nucleico recombinante, vacina, e, método para ajudar na proteção de um frango contra vírus
WO2015052543A3 (en) Malaria vaccination
MX2016013299A (es) Composiciones de vacuna.
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
MX2017016896A (es) Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos.
MX2022003590A (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9.
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
MX363149B (es) Vacunas de nucleoproteina de la influenza.
CO6700818A2 (es) Vectores de parapoxvirus
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
DK3471766T3 (da) Rekombinante, ikke-patogene mareks sygdomsviruskonstrukter, der koder for infektiøs laryngotracheitisvirus- og infektiøs bursitis virus-antigener patentkrav
PE20150323A1 (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con el
EA201892385A1 (ru) Модификация сконструированных полипептидов гемагглютинина вируса гриппа
PE20160940A1 (es) Newcastle recombinante expresando las proteinas s del virus de bronquitis aviar y sus aplicaciones
BR112022002082A2 (pt) Formulações de vacina contra o chikungunya
TH156282A (th) ไวรัสโรคมาเร็กซ์ที่ถูกดัดแปลงและวัคซีนที่ทำจากมัน

Legal Events

Date Code Title Description
FC Refusal